Serum Omentin-1 and CS846: Biomarkers for Diagnosis and Post-TKA Functional Outcomes in Knee Osteoarthritis
Abstract
Objective: To determine the synergistic diagnostic value of serum Omentin-1 and cartilage oligomeric matrix protein epitope CS846 (CS846) in knee osteoarthritis (KOA) and to explore their link to functional recovery following total knee arthroplasty (TKA), thereby contributing to improved early screening and prognostic strategies.
Methods: We designed a prospective cohort study involving 84 subjects (42 with KOA and 42 healthy controls). The enzyme-linked immunosorbent assay (ELISA) technique was employed to measure serum Omentin-1, CS846, and inflammatory indices (hs-CRP and ESR). Receiver operating characteristic (ROC) curves determined diagnostic efficacy, and a logistic regression model was established for combined diagnosis. Functional outcomes, measured by WOMAC scores, and rehabilitation status was reviewed 6 months post-surgery.
Results: Analysis revealed reduced Omentin-1 and elevated CS846 in KOA patients versus controls. The diagnostic performance (AUC=0.851) of the biomarker combination surpassed that of individual tests. Patients with KL1-2 grades exhibited elevated Omentin-1 but lower CS846 levels compared to those with KL3-4 grades (P<0.05). An inverse correlation was observed between Omentin-1 and inflammatory markers (hs-CRP, ESR), contrasting with the positive correlation for CS846. Post-treatment, poor recovery was associated with more pronounced decreases in Omentin-1 and increases in CS846 (P<0.05). The combined model effectively predicted suboptimal rehabilitation outcomes (AUC=0.857).
Conclusion: The synergistic use of serum Omentin-1 and CS846 biomarkers boosts early detection capability for KOA while accurately forecasting post-TKA functional outcomes.
Copyright (c) 2025 Yingzhao Qi, Zhixin Liu, Fengli Sun, Ran Liu, Jianfeng Deng, Longfei Hao, Jiayu Wang, Juyuan Gu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.